The GP2 peptide: a HER2/neu-based breast cancer vaccine

J Surg Oncol. 2012 Apr 1;105(5):452-8. doi: 10.1002/jso.21723.

Abstract

Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2-based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / prevention & control*
  • Cancer Vaccines / adverse effects
  • Cancer Vaccines / immunology*
  • Clinical Trials as Topic
  • Dimerization
  • Female
  • GPI-Linked Proteins / adverse effects
  • GPI-Linked Proteins / immunology*
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • HLA-A2 Antigen / immunology*
  • Humans
  • Immunoglobulin G / immunology
  • Immunotherapy / methods
  • Mucin-1 / metabolism
  • Peptide Fragments / metabolism
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / metabolism*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Cancer Vaccines
  • GP2 protein, human
  • GPI-Linked Proteins
  • HLA-A2 Antigen
  • Immunoglobulin G
  • MUC-1 protein, human (950-958)
  • Mucin-1
  • Peptide Fragments
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Receptor, ErbB-2
  • Trastuzumab